The estimated Net Worth of Kai Xian Chen is at least $1.15 Million dollars as of 12 March 2021. Chen Chen owns over 4,302 units of Zai Lab stock worth over $531,959 and over the last 4 years he sold ZLAB stock worth over $613,164. In addition, he makes $0 as Independent Director at Zai Lab.
Chen has made over 1 trades of the Zai Lab stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 4,302 units of ZLAB stock worth $613,164 on 12 March 2021.
The largest trade he's ever made was selling 4,302 units of Zai Lab stock on 12 March 2021 worth over $613,164. On average, Chen trades about 860 units every 0 days since 2021. As of 12 March 2021 he still owns at least 24,662 units of Zai Lab stock.
You can see the complete history of Chen Chen stock trades at the bottom of the page.
Prof. Chen Kai-Xian Ph.D. serves as Independent Director of the Company. He served as a member of the National Committee of the Chinese People’s Political Consultative Conference. From 2005 to 2014, Professor Chen served as President of Shanghai University of Traditional Chinese Medicine. From 2011 to 2018, Professor Chen served as President of the Shanghai Association for Science and Technology. Prior to that, from 1993 to 2004, Professor Chen served as Deputy Director and later, Director of Shanghai Institute of Materia Medica, or SIMM, Chinese Academy of Sciences. Professor Chen has as also served as Principal Scientist for two National Basic Research Programs by the MOST. Since 2001, professor Chen has served successively as the member of the Chief Specialists Board and the deputy Chief Technical Officer of the major science and technology projects "innovative drugs and modernization of traditional Chinese medicine" and "Innovative Drug Research & Development ", where he participated in the organization and promotion of new drug research and development for China’s 10th -13th Five Year Plans. In 1999, Professor Chen was elected as a member of the Chinese Academy of Sciences. Prior to that, from 1985 to 1988, he conducted postdoctoral research at Institut de Biologie Physico-Chimique in Paris. Professor Chen started his academic career at SIMM as an Associate Professor, where he later reached the level of Full Professor. Professor Chen received his Master and Ph.D. Degree at the Chinese Academy of Science, and his Bachelor of Science from Fudan University.
Chen Xian is 74, he's been the Independent Director of Zai Lab since 2018. There are 1 older and 23 younger executives at Zai Lab. The oldest executive at Zai Lab Limited is John Diekman, 77, who is the Independent Director.
Kai's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis, and John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Zai Lab executives and other stock owners filed with the SEC include: